BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th.Analysts expect Beam Therapeutics to ...

In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against the other best performing pharma stocks so far in 2025. On February 20, Jared Holz ...

Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...

In the preceding three months, 4 analysts have released ratings for Beam Therapeutics BEAM, presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...